Alethio's $90 Million Bet That the Mutation Was Never the Point
Alethio Therapeutics closed a $90 million Series A to push ATX-011, a first-in-class antibody against G6B, into Phase 1/2a for essential thrombocythaemia. The target sits on the stem cells that drive MPNs, regardless of mutation.